… ProQR to Present at Upcoming SVB Leerink Conference LEIDEN, … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived webcasts will be …
… ProQR to Present at Cowen Health Care Conference LEIDEN, … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Presentations at the OTS Annual Meeting … on QR-110 clinical data in LCA10 David Rodman, MD, EVP of R&D of ProQR, will give a presentation on the recent clinical data …
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
… ProQR Announces Year End 2023 Operating and Financial Results … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We announced our initial pipeline programs, AX-0810 …
… ProQR Announces First Quarter 2023 Operating and Financial … & CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company … 31, 2023, and provided a business update. “During our R&D event in Q1, we provided a comprehensive update on how …
… ProQR Announces Results for the Second Quarter of 2017 Key … in need,“ said Daniel de Boer, Chief Executive Officer of ProQR. “We have made significant progress in all of our … the Axiomer ® platform technology we announced at our R&D day. I’m proud of our scientific team to have invented …
… ProQR Announces Third Quarter 2022 Operating and Financial … to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 Management Team appointments … & CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a …
Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United S
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026